title: Flavonoids as promising lead compounds in type 2 diabetes mellitus: molecules of interest and structure-activity relationship.
abstract: There is evidence that hyperglycemia results in the generation of reactive oxygen species, leading to oxidative stress in various tissues, including vascular system. An important link between oxidative stress, inflammatory response and insulin activity is now well established. The ability of antioxidants to protect against the deleterious effects of hyperglycemia and also to improve glucose metabolism and intake must be considered as leads of choice in diabetes treatment. In addition to their antioxidative activity, many flavonoids were demonstrated to act on biological targets involved in type 2 diabetes mellitus such as: α-glycosidase, glucose cotransporter or aldose reductase. In this context, flavonoids behaving as antioxidants were studied as potential drugs by acting as biological targets involved in diabetes development. In this review, we propose to shed light on antioxidants flavonoids investigated as antidiabetics. A special focus was made to address the structure-activity relationship related to the effect of these naturally occurring molecules on different targets involved in diabetes development.
authors.affiliation: Université de Grenoble I/CNRS, UMR 5063, Département de Pharmacochimie Moléculaire, BP 53 F-38041 Grenoble Cedex 9, France.
authors.forename: E
authors.initials: E
authors.lastname: Nicolle
authors.forename: F
authors.initials: F
authors.lastname: Souard
authors.forename: P
authors.initials: P
authors.lastname: Faure
authors.forename: A
authors.initials: A
authors.lastname: Boumendjel
mesh_terms: D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors; D000975:Antioxidants / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005419:Flavonoids / Q000627:therapeutic use*; D005947:Glucose / Q000378:metabolism; D051246:Glucose Transport Proteins, Facilitative / Q000037:antagonists & inhibitors / Q000378:metabolism; D017127:Glycation End Products, Advanced / Q000037:antagonists & inhibitors; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D018384:Oxidative Stress / Q000187:drug effects* / Q000502:physiology; D021281:Quantitative Structure-Activity Relationship; D017382:Reactive Oxygen Species / Q000378:metabolism; D013329:Structure-Activity Relationship
chemical_list: D000975:Antioxidants; D005419:Flavonoids; D051246:Glucose Transport Proteins, Facilitative; D017127:Glycation End Products, Advanced; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D017382:Reactive Oxygen Species; D000449:Aldehyde Reductase; D005947:Glucose